Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS
نویسندگان
چکیده
منابع مشابه
Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.
We report the first case of chronic myeloid leukemia (CML) in a patient with multiple sclerosis (MS) diagnosed within two years of receiving mitoxantrone therapy. Previously only acute forms of leukemia particularly acute promyelocytic leukemia (APL) have been associated with mitoxantrone treatment in MS. This underscores the need for only using mitoxantrone in severe treatment-unresponsive cas...
متن کاملAdverse events associated with ERCP.
Vinay Chandrasekhara, MD, Mouen A. Khashab, MD, V. Raman Muthusamy, MD, FASGE, Ruben D. Acosta, MD, Deepak Agrawal, MD, MPH, David H. Bruining, MD, Mohamad A. Eloubeidi, MD, MHS, FASGE, Robert D. Fanelli, MD, FACS, FASGE, SAGES Representative, Ashley L. Faulx, MD, FASGE, Suryakanth R. Gurudu, MD, FASGE, Shivangi Kothari, MD, Jenifer R. Lightdale, MD, MPH, FASGE, NASPGHAN Representative, Bashar ...
متن کاملEarly onset cardiotoxicity associated with mitoxantrone in patients with multiple sclerosis.
M sclerosis (MS) is an autoimmune disease, involving predominantly the white matter of the brain and spinal cord. Approximately 85% of patients initially experience one or more relapses followed by complete or incomplete recovery; this clinical pattern is called the relapsing–remitting phase. Over 10 years, roughly 50% of these patients experience a transition to the secondary progressive phase...
متن کاملCardiotoxicity associated with chemotherapy: Need for treatment and prophylaxis role
Cardiotoxicity is a well-known potential side effect of several chemotherapeutic agent. Patients undergoing chemotherapy highly exposed to cardiac complications. Chemotherapeutic agents like anthracycliines, cyclophosphamide and signaling inhibitors like human monoclonal antibodies and tyrosine kinase inhibitors worsen cardiovascular system. A number of cardiovascular events occur during cardio...
متن کاملBisphosphonate-associated adverse events.
The adverse events of the nitrogen-containing bisphosphonates are reviewed. Oral bisphosphonates (alendronate, risedronate and ibandronate), mainly used for the treatment of osteoporosis, have been associated with adverse events from the upper gastrointestinal tract, acute phase response, hypocalcaemia and secondary hyperparathyroidism, musculoskeletal pain, osteonecrosis of the jaw and ocular ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology
سال: 2010
ISSN: 0028-3878,1526-632X
DOI: 10.1212/wnl.0b013e3181e0f7e6